Atherosclerosis Risk in Communities

Lore & Background

The ARIC Study enrolled participants from four U.S. communities: Forsyth County, North Carolina; Jackson, Mississippi; suburbs of Minneapolis, Minnesota; and Washington County, Maryland. Participating organizations include four field centers (Wake Forest Baptist Medical Center, University of Mississippi Medical Center, University of Minnesota, Johns Hopkins University), a data coordinating center (University of North Carolina at Chapel Hill), and many collaborating centers and laboratories. The initial study visit took place in 1987-1989, with subsequent visits in 1990-1992, 1993-1995, 1996-1998, and 2011-2013.

Reader's Guide

The ARIC Study has published over 2,300 peer-reviewed journal articles in diverse areas of clinical and population research. Its data have become an important resource for the study of heart disease, kidney disease, diabetes, and cognitive decline. These data have also contributed to clinical practice guidelines and policy statements. The study is registered at ClinicalTrials.gov under trial identifier NCT00005131. Its prospective, biracial design and long follow-up have allowed researchers to examine risk factors and outcomes across multiple chronic conditions, making it a foundational resource in cardiovascular epidemiology.

Did You Know?

• The ARIC Study enrolled 15,792 middle-aged men and women aged 45–64 years.
• The study includes four field centers: Wake Forest Baptist Medical Center, University of Mississippi Medical Center, University of Minnesota, and Johns Hopkins University.
• The fifth study visit took place in 2011-2013, more than two decades after the initial visit in 1987-1989.
• ARIC data have contributed to clinical practice guidelines and policy statements.

The Silent Decades — Onset and Discovery

Atherosclerosis is one of medicine's great deceptions: it begins quietly, often in childhood, and can remain completely silent for decades. Fibrous and gelatinous lesions have been documented in the coronary arteries of children, and fatty streaks in juveniles, yet the arteries themselves enlarge at plaque sites to preserve blood flow, masking the damage. Most plaque ruptures go unnoticed until enough narrowing or clotting finally blocks an artery. The result is that the majority of patients first learn they have the disease only when a heart attack or stroke strikes. A 2004 analysis of U.S. data revealed that roughly 66 percent of men and 47 percent of women experienced a heart attack or sudden cardiac death as their very first sign of atherosclerotic cardiovascular disease. The Korean War autopsy of 300 soldiers, averaging just 22.1 years old, found gross coronary arteriosclerosis in 77.3 percent. By age 65, nearly every person carries some degree of the condition, making it the leading cause of death and disability in developed nations.

A Web of Risk — The Multifactorial Landscape

The precise origin of atherosclerosis remains elusive, and researchers describe it as multifactorial rather than attributable to a single trigger. At its core, the disease is a chronic inflammatory process in which elevated LDL cholesterol drives the accumulation of atheromatous plaques—mixtures of fat, cholesterol, immune cells, calcium, and other blood components—within arterial walls. Yet the web of contributors extends far beyond lipids. High blood pressure, diabetes, active and passive smoking, obesity, an unhealthy diet, and sedentary lifestyle habits all feed the process. Inflammatory biomarkers and elevated apolipoprotein B–containing lipoproteins add further layers. Genetics plays a role as well: family history and specific inherited traits can create a strongly increased predisposition. Remarkably, evidence suggests the susceptibility is woven into human biology itself, with origins possibly tracing to CMAH genetic mutations that arose more than two million years ago among hominin ancestors. First formally described in 1575, atherosclerosis is thus both a modern epidemic and an ancient vulnerability.

When Arteries Speak — Organ-Specific Consequences

Because atherosclerosis can lodge in any arterial bed, its symptoms are as varied as the organs they threaten. In the coronary arteries, marked narrowing produces angina—chest pain accompanied by shortness of breath, sweating, nausea, dizziness, or palpitations—and can trigger arrhythmias, the heart beating either too slowly or too quickly. The carotid arteries, which feed the brain and neck, present a different constellation: weakness, difficulty thinking clearly, slurred speech, blurred vision, numbness in the face or limbs, severe headache, and even loss of consciousness, all hallmarks of impending or actual stroke. Peripheral arteries serving the legs, arms, and pelvis manifest as pain and numbness in the extremities. The renal arteries, when narrowed by plaque, quietly reduce kidney perfusion, eventually leading to chronic kidney disease that stays symptomless until late stages. Crucially, these symptoms only emerge once narrowing or clotting has progressed far enough to genuinely impede oxygen-rich blood flow, which is why the disease so often announces itself through a catastrophic event rather than a gradual warning.

From Prevention to Intervention — Managing the Disease

Because atherosclerosis is chronic and progressive, management spans a wide spectrum from lifestyle modification to major surgery. Prevention guidelines emphasize eating a healthy diet, regular physical activity, abstaining from smoking, and maintaining a normal body weight—steps that address several of the modifiable risk factors simultaneously. Once plaques are established, pharmacotherapy becomes central: statins and other cholesterol-lowering agents, antihypertensive medications, and anticoagulant therapies to reduce the risk of clot formation all form the backbone of medical management. As the disease advances and arteries narrow further, less invasive measures give way to interventional procedures. Percutaneous coronary intervention, coronary artery bypass grafting, and carotid endarterectomy represent the more aggressive end of the therapeutic spectrum, each tailored to the specific artery and severity of blockage. Diagnosis itself is multimodal, relying on physical examination, electrocardiography, exercise stress testing, and other assessments chosen according to which vessels are suspected to be affected. The treatment pathway thus mirrors the disease's own gradual escalation.